A common characteristic of glycopeptide-intermediate-resistant Staphylococcus aureus (GISA) is a thickened cell wall, containing fewer cross-links and hence an abundance of D-Ala-D-Ala termini of the pentapeptide. A further phenomenon observed in GISA has been lowered or nonexistent expression of pbp4, which has both transpeptidase and D,D-carboxypeptidase activity, cleaving terminal D-alanine residues from uncross-linked muropeptides (3) . Reduced expression of pbp4 may contribute to production of thickened and altered peptidoglycan and the intermediate resistance to glycopeptides exhibited in these strains.
Expression of pbp4 and/or activity of PBP4 has been studied mainly in laboratory-derived strains and less well in clinical GISA isolates. Initial penicillin-binding protein (PBP) studies showed an increase in PBP4 levels (as well as those of other PBPs) in one out of three laboratory-derived GISA isolates (4) . However, in a vancomycin-resistant mutant (VM), a teicoplanin-resistant mutant (TNM), and a vancomycin-and teicoplanin-resistant mutant (TM), no detectable PBP4 was found (9) , and other laboratory-generated vancomycin-resistant "step mutants" showed decreased PBP4 levels with increasing vancomycin MICs (10). More recently, three clinical GISA strains (including Mu50) were reported to have undetectable PBP4 levels, a fourth was found to contain lowered PBP4 levels (1), and a further clinical GISA strain exhibited a reduction in both PBP3 and PBP4 levels (6) .
Nine clinical GISA strains (Mu50, Michigan [MI], New Jersey [NJ], SL, SW307, GL3700, GL3759, LIM3, and PC3) belonging to two clonal groups (New York/Japanese and Brazilian/Portuguese), 11 heterogeneous GISA (hGISA) strains (Mu3, SW309, AGN, NW1018, SL6096, LIM1, PC1, SMH2, LLE, 23SH, and DF) belonging to five clonal groups (Brazilian/Portuguese, Australia, UK EMRSA 2 ϩ 6, Iberian, and UK EMRSA 15), and 7 glycopeptide-susceptible S. aureus (GSSA) strains belonging to three clonal groups (UK EMRSA 15, UK EMRSA 2 ϩ 6, and Brazilian/Portuguese) (2) were studied in triplicate assays, using reverse transcriptase PCR with customized primers (CTGTAAG CACTGCTAGAGAC/CGTTGCTTCTCGCCACCAAG) and gel electrophoresis, to evaluate the expression levels of pbp4 in exponential-phase growth.
Three GISA strains (MI, GL3759, and SL) and one hGISA strain (AGL) exhibited 80% reductions in pbp4 expression, while three other GISA strains (Mu50, NJ, and SW307) and two hGISA strains (Mu3 and NW1018) exhibited 20% reductions in pbp4 expression, compared with the expression levels in GSSA strains (Fig. 1) .
The expression of pbp4 appears to vary according to the strain. The band intensities of the related strain set LLA (GSSA) and LLE (hGISA) decreased slightly with increasing vancomycin-intermediate resistance. However, in two other clinically related hGISA and GISA strain sets (PC1/PC3 and LIM1/LIM3), no variation in expression was observed (Fig. 1,  compare lanes 22 and 23 and lanes 24 and 25) .
Although expression of pbp4 appears to be reduced or nonexistent in the few strains previously studied, this study reveals that not all GISA strains show reduced pbp4 expression. Also, the variety in pbp4 expression is not indicative of any particular clonal type. In this study, pbp4 expression levels in four clinical GISA strains correlated well with those of the same strains studied previously (NJ, Mu50, MI, and Mu3) (1) .
Although loss of pbp4 gene function was attributed to formation of a premature stop codon in TNM and duplication of a 51-nucleotide segment in TM and VM (9), these mutations were not found in 41 clinical isolates with low-level teicoplanin resistance, suggesting either that pbp4 expression is unchanged in clinical GISA isolates or that if activity levels of PBP4 are lower, the decrease reflects other changes to the pbp4 gene or its expression (5) .
It is possible therefore that the different pbp4 expression levels seen in clinical GISA strains are strain specific or that posttranslational modification occurs. Nonetheless, lowered PBP4 levels may play a role in vancomycin-intermediate resistance in some strains, explaining the fewer cross-links seen in the peptidoglycan of those strains and the higher levels of un-cross-linked pentapeptide chains containing D-Ala-D-Ala termini (6, 7, 8) .
